文献速递白血病造血干细胞移植与细胞治疗

接受异基因造血干细胞移植的急性髓系白血病患者疾病复发时的突变分析

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2016-12-14

该研究对113例接受异基因造血干细胞移植的急性髓系白血病成人患者诊断时35个基因进行重测序,49例复发;WT1、DNMT3A、FLT3 ITD和TP53突变与复发风险增加相关,IDH1突变与复发风险降低相关;29例患者诊断与复发时骨髓突变谱比较显示13例复发时突变谱改变。

要点

  • 113例患者中102例(90%)检出262个突变,49例复发。
  • WT1突变(P=0.018)、DNMT3A突变(P=0.045)与复发风险增加相关。
  • IDH1突变与疾病复发风险降低相关(P=0.018)。

核心结论

  • 这些观察若能在更大规模研究中得到证实,可能有助于设计减少移植后复发的新策略,并提示移植后采用广谱抗肿瘤特异性干预可能具有潜在重要性,而非仅基于诊断时突变谱的靶向治疗。

研究设计与样本

  • 对113例接受异基因造血干细胞移植的急性髓系白血病成人患者在诊断时重测序35个基因,其中49例复发。
  • 对29例患者额外比较诊断时与复发时骨髓的突变谱以研究复发时克隆结构变化。

主要发现

  • 在102/113例(90%)患者中检出262个突变。
  • WT1突变(P=0.018)、DNMT3A突变(P=0.045)、FLT3 ITD(P=0.071)和TP53突变(P=0.06)患者复发风险增加。
  • IDH1突变与疾病复发风险降低相关(P=0.018)。
  • 29例患者中13例复发时突变谱发生改变。
  • 9例患者中复发时存在的突变在诊断时未检出;15例患者中移植后检出而诊断时未检出的突变,有2例在移植前即刻可检出。

临床怎么用

  • 作者认为这些观察若能在更大规模研究中得到证实,可能有助于设计减少移植后复发的新策略,并提示移植后采用广谱抗肿瘤特异性干预可能具有潜在重要性,而非仅基于诊断时突变谱的靶向治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disease relapse is the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML). To identify AML-associated genes prognostic of AML relapse post-allo-SCT, we resequenced 35 genes in 113 adults at diagnosis, 49 of whom relapsed. Two hundred sixty-two mutations were detected in 102/113 (90%) patients. An increased risk of relapse was observed in patients with mutations in WT1 (P = .018), DNMT3A (P = .045), FLT3 ITD (P = .071), and TP53 (P = .06), whereas mutations in IDH1 were associated with a reduced risk of disease relapse (P = .018). In 29 patients, we additionally compared mutational profiles in bone marrow at diagnosis and relapse to study changes in clonal structure at relapse. In 13/29 patients, mutational profiles altered at relapse. In 9 patients, mutations present at relapse were not detected at diagnosis. In 15 patients, additional available pre-allo-SCT samples demonstrated that mutations identified posttransplant but not at diagnosis were detectable immediately prior to transplant in 2 of 15 patients. Taken together, these observations, if confirmed in larger studies, have the potential to inform the design of novel strategies to reduce posttransplant relapse highlighting the potential importance of post-allo-SCT interventions with a broad antitumor specificity in contrast to targeted therapies based on mutational profile at diagnosis.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Quek L, Ferguson P, Metzner M, et al. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2016. PMID: 29296935. doi:10.1182/bloodadvances.2016000760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。